Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cells

Table 2 Changes in C-peptide levels of the T1D subjects after treatment at 12 weeks.

Patient No.	C-peptide (ng/ml)	Changes in C-peptide levels (ng/ml)
Group A:
1	0.56	↑ 0.26
2	0.98	↑ 0.42
3	0.54	↑ 0.42
4	1.1	↑ 0.46
5	0.52	↑ 0.34
6	0.78	↑ 0.60
Mean	0.75	↑ 0.42
(SD)	(0.24)	(0.12)
Group B
7	0.25	↑ 0.24
8	0.11	↑ 0.10
9	0.28	↑ 0.27
10	0.43	↑ 0.42
11	0.11	↑ 0.10
12	0.12	↑ 0.11
Mean	0.22	↑ 0.21
(SD)	(0.13)	(0.13)
Control Group
13	0.41	↑ 0.04
14	0.38	↓ 0.17
15	0.35	↑ 0.05
Mean	0.38	↓ 0.03
(SD)	(0.03)	(0.12)

Levels of plasma C-peptide before treatment served as baseline for comparison. The level of C-peptide was increased (↑); the level of C-peptide was decreased (↓).

ISSN: 1741-7015